Loading…
CDMO manufacturing complex injectables, ophthalmics and biologics for global pharma clients, spun off from Strides Pharma.
CDMO manufacturing complex injectables, ophthalmics and biologics for global pharma clients, spun off from Strides Pharma.
In one line: A newly independent Indian CDMO.
Moat: narrow (regulatory licence, process know-how). Specialized regulated manufacturing facilities for complex dosage forms are costly for new entrants.
Headquarters: Bengaluru, India · Employees: 2,289
Size OneSource Specialty Pharma (ONESOURCE.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.94B, the 376th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹1,600 on 6 Nov 2026.
Performance Over six months the shares fell 11.9%, against -1.9% for the median peer and 0.0% for the India market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 10.7% over the last twelve months (peer median +10.0%); the operating margin is 6.4% (peer median 15.0%).
Valuation It trades at 45.0× forward earnings against a peer median of 20.4× (4th most expensive of 19).
Capital Return on invested capital runs 14.6 points below its cost of capital (15.7% WACC).
Next results Next results expected around 22 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹16.8B | ₹14.2B | ₹14.4B | ₹1.72B | ₹387M |
| Revenue growth | — | -2% | +740% | +344% | — |
| Gross profit | ₹5.92B | ₹3.85B | ₹4.53B | -₹1.94B | -₹1.48B |
| EBITDA | ₹3.96B | ₹2.75B | ₹4.65B | -₹1.98B | -₹2.00B |
| Net income | -₹16.2M | -₹738M | -₹180M | -₹3.91B | -₹8.00B |
| Free cash flow | n/a | -₹6.80B | -₹3.39B | -₹2.71B | -₹3.09B |
| Capital expenditure | n/a | ₹5.69B | ₹1.28B | ₹638M | ₹440M |
| Total debt | ₹17.5B | ₹15.0B | ₹9.42B | ₹5.71B | ₹8.64B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| OneSource Specialty Pharma ONESOURCE.NS | $1.94B | -12% | +11% | 6% | 45.0× | n/a |
| Piramal Pharma PPLPHARMA.NS | $3.37B | +30% | +9% | 3% | 159.9× | n/a |
| Syngene International SYNGENE.NS | $1.78B | -11% | -6% | 13% | 67.8× | 35.3% |
| Gland Pharma GLAND.NS | $5.53B | +69% | +18% | 20% | 39.0× | 28.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ONESOURCE.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.7% | -0.1% | 8th highest of 21 |
| 6-month return | -11.9% | -1.9% | 8th lowest of 21 |
| Distance from 52-week high | -16.9% | -27.8% | 7th highest of 21 |
| Revenue growth (TTM) | +10.7% | +10.0% | 11th highest of 21 |
| Operating margin | 6.4% | 15.0% | 6th lowest of 21 |
| Forward P/E | 45.0× | 20.4× | 4th most expensive of 19 |
| ROIC minus cost of capital | -14.6 pp | +0.4 pp | 2nd lowest of 21 |
| EV / EBITDA | 50.6× | 14.7× | most expensive of 9 |
| Net debt / EBITDA | 4.3× | -1.1× | most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.94B | -12% | +11% | 6% | 45.0× | n/a | n/a |
| Harmony Biosciences HRMY | United States | $1.93B | +7% | +20% | 22% | 8.6× | -10.9% | +40.3% |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.95B | 0% | +13% | 27% | 13.0× | -0.5% | +16.7% |
| Alivus Life Sciences ALIVUS.NS | India | $1.92B | +32% | +8% | 31% | 24.4× | 20.4% | +6.2% |
| Shilpa Medicare SHILPAMED.NS | India | $1.95B | +113% | +28% | 21% | 62.1× | n/a | n/a |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.92B | +28% | +15% | 31% | 24.6× | 29.3% | +15.7% |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.91B | -25% | +17% | 33% | 13.7× | 6.0% | +29.1% |
| Sino Biological 301047.SZ | China | $1.98B | +50% | +20% | 17% | 63.8× | 36.8% | -15.1% |
| Maze Therapeutics MAZE | United States | $1.90B | +29% | +700% | -728% | n/a | n/a | n/a |
| ApicHope Pharmaceutical 300723.SZ | China | $1.99B | -28% | -28% | -50% | 25.7× | 14.0% | -11.0% |
| Shenzhen Hepalink Pharmaceutical 9989.HK | Hong Kong | $1.89B | -18% | -1% | 8% | 8.3× | 0.4% | -0.2% |
| Sarepta Therapeutics SRPT | United States | $1.88B | -11% | -20% | -3% | n/a | 11.9% | +32.4% |
| United Laboratories International 3933.HK | Hong Kong | $2.00B | -19% | -13% | 5% | 14.5× | 3.7% | +7.8% |
| BrightGene Bio-Medical Technology 688166.SS | China | $2.00B | -51% | +14% | 7% | 87.6× | 38.5% | +9.2% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $2.01B | -9% | -9% | 30% | 19.3× | 9.1% | +9.3% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.01B | +24% | +20% | 12% | 24.4× | 25.0% | +6.5% |
| Pfizer PFIZER.NS | India | $1.87B | -19% | +12% | 34% | 21.5× | 11.2% | +2.4% |
| Grand Pharmaceutical 0512.HK | Hong Kong | $2.01B | -27% | +7% | 13% | 9.8× | 1.2% | +14.1% |
| Qingdao Baheal Medical 301015.SZ | China | $2.02B | +4% | -6% | 8% | 23.5× | 11.9% | +5.0% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.02B | +7% | +5% | 22% | 15.9× | -4.8% | +10.6% |
| China National Accord Medicines 000028.SZ | China | $1.85B | -4% | 0% | 2% | 11.1× | -9.4% | +4.2% |